1. Albisser, A. M., Leibel, B. S., Ewart, T. G., Davidovac, A., Botz, C. K. andZingg, W. (1974a) An artificial endocrine pancreas.Diabetes,23, 389–396.
2. Albisser, A. M., Leibel, B. S., Ewart, T. G., Davidovac, A., Botz, C. K., Zingg, W., Schipper, H. andGander, R. (1974b) Clinical control of diseases by the artificial pancreas.,23, 396–404.
3. Albisser, A. M., Perlman, K., Marliss, E. B. andZinman, B. (1983) Achieving normoglycaemia by closed- and open-loop insulin delivery systems. InArtificial systems for insulin delivery.Brunetti, P., Alberti, K. G. M. M., Albisser, A. M., Hepp, K. D. andMassi Benedetti, M. (Eds.) Raven Press, New York, 173–179.
4. Bending, I. J., Pickup, J. C., Collins, A. C. G. andKeen, H. (1984) Rarity of the dawn phenomenon in diabetics treated by continuous subcutaneous insulin infusion.Diabetes,33, Suppl. 1, 854.
5. Bending, J. J., Pickup, J. C., Keen, H., Rothwell, D. andSutherland, I. A. (1983) Meeting the problems of firstgeneration insulin infusion pumps: clinical trial of a new miniature infuser.Diabetes Care,6, 452–458.